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Abstract
Mesalazine (5-ASA) is an aminosalicylate anti-
inflammatory drug capable of inducing m-protocad-
herin, a protein expressed by colorectal epithelial
cells that is downregulated upon malignant transfor-
mation. Treatment with 5-ASA restores m-protocad-
herin expression and promotes the sequestration of
b-catenin to the plasma membrane. Here, we show
that 5-ASA–induced m-protocadherin expression is
directly regulated by the KLF4 transcription factor.
In addition, we suggest the existence of a dual mech-
anism whereby 5-ASA–mediated b-catenin inhibition
is caused by m-protocadherin–dependent sequestra-
tion of b-catenin to the plasma membrane and by
the direct binding of KLF4 to b-catenin. In addition,
we found that 5-ASA treatment suppresses the expres-
sion of miR-130a and miR-135b, which target KLF4
mRNA, raising the possibility that this mechanism
is involved in the increased expression of KLF4
induced by 5-ASA. Cancer Prev Res; 11(8); 503–10.
2018 AACR.
Introduction
Colorectal cancer arises as a result of a multistep
process in which well-characterized genetic and epige-
netic alterations, causing the activation of proto-onco-
genes and the inactivation of tumor-suppressor genes,
occur in a sequential order (1). Chemoprevention with
Non-Steroidal Anti-Inflammatory Drugs (NSAID) is a
strategy currently used to inhibit the development of
colorectal cancer in patients with pre-malignant condi-
tions (2); however, the systemic and gastrointestinal
toxicity of these compounds drastically limits their
administration in clinical protocols requiring long-term
treatments. A number of drugs characterized by a similar
pharmacological activity, but devoid of the severe side
effects of NSAIDs, are currently under investigation; one
such drug is Mesalazine (5-Aminosalicylic Acid or 5-ASA;
ref. 2) that exerts its chemopreventing effect by inhibiting
the b-catenin signaling pathway, resulting in reduced
proliferation and increased differentiation. These effects
were observed in different tumor types, including colo-
rectal cancer (3, 4). The molecular mechanisms under-
lying 5-ASA action are not clearly understood. In the
past few years, our research group has contributed to
clarify this issue demonstrating the involvement of a
protein named m-protocadherin, that is encoded by
the MUCDHL gene. The expression of this protein is
silenced during colorectal cancer carcinogenesis (5, 6)
but is upregulated upon treatment with 5-ASA and acts
by sequestering b-catenin to the plasma membrane.
Additional experiments performed in our laboratory
indicate that the expression of m-protocadherin is nega-
tively regulated by b-catenin, suggesting that a mecha-
nism of reciprocal inhibition regulates the activity of
these two proteins (7).
Kruppel-like factor 4 (KLF4) is a transcription factor
highly expressed in the adult intestine (8) and is critically
important in the process of differentiation (9). KLF4 inter-
acts with b-catenin and inhibits Wnt signaling (10). Given
the critical role of b-catenin in mediating Wnt signaling
and in the development of colorectal cancer, a better
understanding of the mechanism of KLF4-mediated inhi-
bition may lead to novel therapies for colorectal cancer.
However, the precise molecular mechanisms of how
KLF4 inhibits b-catenin are not entirely clear.
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In this study, we further analyzed the chemopreventing
role of 5-ASA. Our data suggest that this compound is
capable of inducing KLF4 expression, which, in turn,
inhibits Wnt/b-catenin signaling by preventing the inter-
action of b-catenin with TCF4 and by directly inducing
m-protocadherin expression leading to b-catenin seques-
tration to the plasma membrane.
Materials and Methods
Microarray analysis
We analyzed the expression of KLF4-induced genes
in untreated and 20 mmol/L 5-ASA–treated CaCo2
cells, as previously described (6), using the Affymetrix
Human HG-U133 plus2 GeneChip array, according
to Affymetrix standard protocols (Thermo Fisher
Scientific; ref. 11).
Cell lines
CaCo2, HT29, and HEK293T cell lines were obtain-
ed from the ATCC and cultured in DMEM medium
(Euroclone), supplemented with 10% heat-inactivated
FBS (Sigma-Aldrich) and 1 mmol/L L-Glutamine
(Euroclone).
5-ASA (SofarFarm S.p.A.) was dissolved in complete
DMEMmedium at the concentration of 10 to 20 mmol/L
and experiments were performed protected from light.
Protein extracts preparation and Western blot analysis
Total extracts of CaCo2 cells were obtained as previ-
ously reported (12). Briefly, 50 mg of protein extracts
were loaded onto 10% SDS-polyacrylamide gel and
blotted as described (13). Membranes were pre-blocked
in blocking solution, supplemented with 5% non-fat
milk (Regilait), for 1 hour at room temperature and
then incubated with the appropriated primary antibody
diluted according to the manufacturer's protocol, fol-
lowed by a 1-hour incubation at room temperature with
a specific secondary antibody conjugated to horseradish
peroxidase (HRP). The following primary antibodies and
the respective dilutions were used for Western blot
analysis: mouse anti–m-protocadherin monoclonal anti-
body (MoAb; A-11, Santa Cruz Biotechnology, Inc.)
1:500 in TBST 3%milk; rabbit anti-KLF4 MoAb (Abcam)
1:1,000 in TBST 1% milk; rabbit anti-TCF4 MoAb (Cell
Signaling Technology, Inc.) 1:1,000 in TBST 5% BSA.
Expression of vinculin was also evaluated with a mouse
anti alfa-vinculin MoAb (Millipore Corporation) to nor-
malize the protein content of the various analyzed sam-
ples. As secondary antibodies, a goat anti-mouse IgG
(Santa Cruz Biotechnology) or a goat anti-rabbit IgG
(Cell Signaling Technology), both conjugated with HRP,
were used respectively at 1:10,000 and 1:15,000 dilu-
tions. Detection of Western blot signals was carried out
using the Westar EtaC enhanced chemi-luminescent sub-
strate (Cyanagen S.r.l.).
Quantitative real-time PCR
Total RNA was extracted from the various analyzed cell
populations bymeans of theQiagen total RNApurification
kits as recommended by the manufacturer (Qiagen) and
RNA concentration was verified by NanoDrop 2000 spec-
trophotometer (Thermo Fisher Scientific). Total RNA
(100 ng) was reverse transcribed using High Capacity
cDNA Archive Kit (Thermo Fisher Scientific) according to
the manufacturer's instructions. Quantitative real-time
PCR (QRT-PCR) was then performed with an ABI PRISM
7900 sequence detection system using TaqMan Universal
PCR Master Mix (Thermo Fisher Scientific) to quantify the
relative levels of mRNA in the samples, as previously
described (14). Evaluation of QRT-PCR signals was even-
tually carried out with the DDCt relative quantification
method, using the GAPDH gene to normalize analyzed
samples. Thermo Fisher Scientific designed also primers
and probe for KLF4, m-protocadherin, p21waf-1, CDX2
and GAPDH amplification. Pairwise comparison between
5-ASA–treated samples transfected with KLF4 siRNA and
control siRNA and between 5-ASA–treated and –untreated
samples transfected with control siRNA, were conducted
using the Student's t-test procedure.
siRNA transfection
Experiments of mRNA silencing were conducted trans-
fecting a mix of three different siRNA oligonucleotides
directed against KLF4 (Sigma-Aldrich) at a concentration
of 100 nmol/L with RNAiMAX reagent (Thermo Fisher
Scientific). The transfection efficiency of CaCo2 cells was
potentiated using the reverse transfection procedure
according to the manufacturer's instructions.
Plasmid expression vector
A full-length KLF4 cDNA was generated by RT-PCR
performed on total RNA extracted from CaCo2 cell line,
using KLF4 DP (50-ACATTAATGAGGCAGCCACC-30) and
KLF4 RP (50-TTCTGGCAGTGTGGGTCATA-30) primers.
Amplification was carried out using a proofreading ther-
mostable DNA polymerase (Roche Diagnostics S.p.A.)
and the amplified fragment was inserted in the pCR2.1
T/A cloning vector (Thermo Fisher Scientific) where it was
fully sequenced to exclude polymerase-induced muta-
tions. KLF4 cDNAs were then excised with EcoRI enzyme
and cloned in the EcoRI site of pcDNA3.1 plasmid
(Thermo Fisher Scientific) resulting in pcDNA3.1-KLF4
construct. The pT81Luc vectors (15), containing KLF4
responsive elements (KRE), were generated as described
below. Modified versions of the following single-strand
oligomers: KRE1 probe 50-TAGTGGGGAGGGTGTGAA-
GG-30; KRE2 probe 50-GGGAGGGAGGTGCTCCCTGG-30,
obtained by adding digested BamHI and SalI sequences
at their ends, were annealed to their complementary
strands, similarly projected. The resulting double-strand
overhang oligomers were then inserted into the BamHI/
SalI digested pT81Luc vector, upstream to a minimal
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promoter and the luciferase reporter gene as previously
described (16). According to these cloning strategies, the
following constructs were generated: pT81LucKRE1,
pT81LucKRE2. Nucleotide sequence analysis of the
plasmids demonstrated that binding sequences had
been inserted as single-copy oligomer.
Luciferase reporter assay
Luciferase transactivation assays were carried out in
HEK293T cells as already described (17, 18). Transient
transfection was conducted with Lipofectamin 2000 plus
(ThermoFisher Scientific), using 200ngof pT81Luc report-
er plasmids, 50 ng of pcDNA3.1-KLF4, 200 ng of pCMVb-
galactosidase (Clontech Laboratories, Inc.) to normalize
for transfection efficiency, and a carrier plasmid to main-
tain a total DNA concentration of 800 ng. After a 48-hour
incubation, cells were lysed according to standard proto-
cols and b-galactosidase and luciferase enzymatic assays
were performed.
TOPFlash Assays were carried out in CaCo2 cells,
using TCF Reporter Plasmid Kit (Addgene). For these
transfections, Lipofectamine 2000 plus (Thermo Fisher
Scientific) was used as a transfection reagent with 250 ng
of TOPFlash or FOPFlash reporter plasmids, 250 ng
of pcDNA3.1-KLF4, 250 ng of pCMVb galacto-
sidase (Clontech Laboratories) and 20 mmol/L 5-ASA
(SofarFarm S.p.A) were used.
Coimmunoprecipitation assay
CaCo2 cells were treated with 20 mmol/L 5-ASA and,
after 96 hours, harvested to extract proteins with
PBSTDS buffer as previously reported 6. 300 mg of total
extract were incubated overnight at 4C with 1 volume of
HNTG Buffer, 30 mL of Protein G Agarose (KPL, Gaithers-
burg, MD) and 2 mg of mouse monoclonal antibody anti–
b-catenin (BD Biosciences) or rabbit polyclonal anti-KLF4
(AbCam). Anti-Mouse or anti–Rabbit-IgG (Santa Cruz
Biotechnology) were used as negative controls. Beads were
extensively washed with HNTG Buffer and samples were
loaded onto 10% SDS-polyacrylamide gel electrophoresis.
Immunoblot analysis was performed with mouse poly-
clonal antibody anti-TCF4 and with rabbit polyclonal
antibody anti-KLF4.
miRNA expression assay
CaCo2 cells were treated with 20 mmol/L 5-ASA
for 96 hours, harvested and total RNA, including
small RNAs, was extracted with the mirVana miRNA
Isolation Kit (Thermo Fisher Scientific). 500 ng of total
RNA was reverse transcribed using Megaplex Pool For
microRNA Expression Analysis (Thermo Fisher Scienti-
fic) as recommended by the manufacturer. The quanti-
tation of 754 human microRNAs was then performed
with TaqMan Array Human MicroRNA AþB Cards Set
v3.0 (Thermo Fisher Scientific) on ABI PRISM 7900 HT
sequence detection system (Thermo Fisher Scientific),
according to the manufacturer's protocol.
miRNA inhibitor transfection
100mmol/L of the followingmirVanamiRNA Inhibitors:
Negative Control #1, miR130a, miR135b and miR130a
and mir135b together, were transfected with Lipofecta-
mine 2000 plus (all Thermo Fisher Scientific) for 48 hours
according to the manufacturer's instructions.
Results
Treatment with 5-ASA induces KLF4 and
m-protocadherin expression
Preliminary findings suggesting that 5-ASAmight induce
KLF4 expression derive from microarray data of CaCo2
cells treated with 20 mmol/L 5-ASA (6). The increase in
KLF4 signal is shown in Fig. 1A. Because these data were
not statistically significant, they had to be further vali-
dated. To do so, the effect of 5-ASA on KLF4 expression
in CaCo2 colorectal cancer cells line was assessed by
QRT-PCR and Western blot. Fig. 1B shows that, compared
with untreated cells, treatment with 5-ASA up-regulates
KLF4 mRNA levels in a dose-dependent manner. Western
blot analysis demonstrated that treatment with 20mmol/L
5-ASA induces a strong upregulation of both KLF4 and
m-protocadherin (Fig. 1C). The same experiment was
also performed on HT29 cells (Fig. 1D and E) confirming
the results observed in CaCo2 cells.
Modulation of KLF4 expression alters m-protocadherin
levels
To investigate whether KLF4 regulates directly
m-protocadherin expression, we analyzed the effects of
KLF4 silencing or overexpression in CaCo2 cells. Fig. 2A
depicts a QRT-PCR showing KLF4, m-protocadherin,
p21waf-1 and CDX2 mRNA levels in KLF4-silenced
CaCo2 cells, untreated or treated with 20 mmol/L
5-ASA. In particular, 5-ASA did not induce m-protocad-
herin expression in CaCo2 cells when KLF4 was
silenced. p21waf-1 and CDX2 are control genes induced
by 5-ASA. Fig. 2B shows the protein levels of KLF4
and m-protocadherin in the same experimental setting.
Again, 5-ASA failed to induce m-protocadherin expression
in KLF4-silenced cells. To further investigate this rela-
tionship, we analyzed m-protocadherin expression in
KLF4-overexpressing CaCo2 cells. By QRT-PCR analysis,
m-protocadherin expression was found to increase in cells
ectopically expressing KLF4, whereas p21waf-1 and CDX2
levels did not change (Fig. 2C); these data suggest that of
these three genes induced by 5-ASA only m-protocadherin
expression might be directly regulated by KLF4.
KLF4 directly regulates m-protocadherin expression
To assess more directly whether KLF4 drives
m-protocadherin expression, we inspected visually its
5-ASA Activates KLF4 in CRC Cells
www.aacrjournals.org Cancer Prev Res; 11(8) August 2018 505
Cancer Research. 
on December 21, 2018. © 2018 American Association forcancerpreventionresearch.aacrjournals.org Downloaded from 
Published OnlineFirst May 24, 2018; DOI: 10.1158/1940-6207.CAPR-17-0382 
promoter for the presence of KLF4 consensus sequence
and identified two putative binding sites (KRE1 and
KRE2; Fig. 3A). The two sequences were separate-
ly cloned in the pT81Luc vector and their role in
m-protocadherin expression was tested by luciferase
reporter assays in HEK293T cells upon co-transfection
with a plasmid driving KLF4 expression. Results of these
assays suggest that only KRE2 may play a role in
KLF4-induced m-protocadherin expression (Fig. 3B).
Although not definitive, these assays strongly suggest
that KLF4 drives directly m-protocadherin expression.
Fig. 3C depicts a Western blot showing KLF4 protein
levels in HEK293T cells co-transfected with KLF4 and
the luciferase reporter.
KLF4 inhibits Wnt/b-catenin transduction pathway by
sequestering b-catenin
On the basis of these findings, it appears that 5-ASA
induces KLF4 expression and that expression of KLF4
is required for 5-ASA–induced m-protocadherin expres-
sion. m-protocadherin inhibits Wnt signaling by seques-
tering b-catenin to the plasma membrane (6). Because
KLF4 is capable of binding and sequestering b-catenin
as well (10), we assessed if this interaction occurs
Figure 1.
Effects of 5-ASA treatment on CaCo2
colorectal cancer cell line. A, 5-ASA
causes an induction of KLF4 mRNA
expression. Cells were untreated (UT)
or treated with 20 mmol/L 5-ASA for
96 hours. mRNA expression was
assessed by DNA microarray. The
signal value is reported on y axis as an
average of three independent
experiments. Although these data are
not statistically significant, they were
intended as a starting point for further
validation. B, 5-ASA induces
upregulation of KLF4 transcripts. Cells
were untreated (UT) or treated with
the indicated doses of 5-ASA for 96
hours and then analyzed byQRT-PCR.
Mean variations of mRNA expression
levels from three independent
experiments are reported in the y-axis
as relative fold-change (relative
quantity). Results are represented as
mean s.e.m. values and asterisks ()
indicate statistically significant results
(P < 0.05). C,Western blot analysis of
5-ASA–treated CaCo2 cells shows an
increased expression of KLF4 and
m-protocadherin. Cells were
untreated (UT) or incubated with the
indicated doses of 5-ASA for 96hours.
Then, KLF4Western blot analysis was
performed on total protein extracts
and normalized to Vinculin
expression. Analyzed proteins are
indicated on the right. D and E, Show
the same experiments described in B
and C, but performed in HT29 cells.
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in 5-ASA–treated colorectal cancer cells. Thus, we
immunoprecipitated KLF4 and b-catenin in CaCo2 cells
treated with 5-ASA and performed a Western blot with
anti–b-catenin and anti-TCF4 antibodies. Results are
shown in Fig. 4A. In particular, Fig. 4A (left) shows that
KLF4 expression is induced by 5-ASA treatment in
the cell lysates used for the co-immunoprecipitation
experiments; Fig. 4A (middle) shows that b-catenin
co-immunoprecipitates with KLF4 only in cells treated
with 5-ASA whereas TCF4 co-immunoprecipitates with
b-catenin only in the absence of 5-ASA (Fig. 4A, right).
This experiment suggests that, following 5-ASA treat-
ment, besides inducing m-protocadherin expression,
Figure 2.
Effect of KLF4 modulation for 5-ASA–induced or basal m-protocadherin
expression. A, CaCo2 cells were transfected with a scramble siRNA
(Cont. siRNA) or a mix of anti-KLF4 siRNAs (KLF4 siRNA) and treated with
5-ASA, to induce m-protocadherin, CDX2 and p21waf-1 expression, or
cultured in absence of the compound (UT). Then, the effect on KLF4,
m-protocadherin, CDX2 and p21waf-1 mRNA levels was analyzed by QRT-PCR.
Results are represented as mean  s.e.m. values of at least five
independent experiments and asterisks () indicate statistically significant
results (P < 0.05). B, Western blot analysis assessing the effect of KLF4
silencing on 5-ASA–induced m-protocadherin expression. C, CaCo2 cells
were transfected with pcDNA KLF4 and its effect on the expression of
m-protocadherin, CDX2 and p21waf-1 was analyzed by QRT-PCR. Results
are represented as in A.
Figure 3.
Luciferase assays performed to validate KRE1- and KRE2-binding elements.
A, 1 Kb proximal promoter region of m-protocadherin gene. Transcriptional
start site and the translation start site (ATG) are indicated by þ1 and by
uppercase letters, respectively. The location of the KRE elements, positioned at
334 bp and at926 bp fromþ1, are highlighted. B, Histograms describing the
results of luciferase assays performed in HEK293T cells transfected with the
pT81Luc reporter plasmids and pcDNA3.1 KLF4 expression vector. The x-axis:
combination of transfected plasmids; y-axis: fold change of b-galactosidase
normalized luciferase values. Bars represent the fold change of the luciferase
activity  s.e.m. of at least three independent experiments and asterisks ()
indicate statistically significant results (p < 0.05). C, Western blot analysis
following plasmids transfection shows an increase of KLF4 expression in
presence of pcDNA KLF4 plasmid.
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KLF4 is also capable of directly sequestering b-catenin.
Moreover, this effect is accompanied by the release of
TCF4 from b-catenin, which prevents its transcription
activity. To further confirm these observations, we per-
formed a reporter assay in CaCo2 cells using the TOP-
flash system that allows to monitor the activity of the
Wnt/b-catenin pathway. In particular, Fig. 4B shows
that these cells display a strong basal activity of the
Wnt/b-catenin pathway. This activity was strongly reduc-
ed by either 5-ASA treatment or KLF4 ectopic expression
(Fig. 4B), confirming the role played by KLF4 in the
regulation of the Wnt/b-catenin pathway.
5-ASA–induced KLF4 expression might depend on
miR-130a and miR-135b downregulation
Weperformed aQRT-PCR analysis of 754 knownmicro-
RNAs in CaCo2 cells treated with 5-ASA. Among the
analyzed miRNAs, 13 (shown in Fig. 5A) were predicted
by Targetscan software to directly target the KLF4 mRNA.
Among these, only miR-130a and miR135b exhibited a
statistically significant decrease in expression upon 5-ASA
treatment of Caco2 cells. Therefore, it is conceivable
that 5-ASA–mediated KLF4 induction might be due to
miR-130a and miR135b downregulation. To test this
hypothesis, CaCo2 cells were transfected with specific
miRNA inhibitors (anti-miR130a and anti-miR135b).
Fig. 5B depicts a Western blot performed 48 hours post-
transfection showing that inhibition of miR-130a and
miR-135b determines an increase of KLF4 expression,
thereby mimicking the effect of 5-ASA. Fig. 5C shows
counts of silenced cells under the same experimental
Figure 4.
Analysis of KLF4 b-catenin interaction by co-immunoprecipitation assay
performed in 5-ASA–treated CaCo2 cells. A, Co-immunoprecipitation
analysis showing the existence of a KLF4–b-catenin protein complex in
5-ASA–treated (20 mmol/L) or –untreated (UT) CaCo2 cells. Western blot
analysis of KLF4, TCF4, and Vinculin was performed on whole-cell extracts
used as control (input, left side of the panel). Western blot analysis of
b-catenin levels was performed on immunoprecipitated samples obtained
with anti-KLF4 and normal rabbit IgG antibodies. TCF4 blotting was
performed on extracts immunoprecipitated with anti–b-catenin and normal
mouse IgG antibodies (right side of the panel). IP, immunoprecipitation;
WB, Western blot. Data are representative of three experiments and
asterisks () indicate statistically significant results (p < 0.05). B, Histograms
showing the results of luciferase assays performed in CaCo2 cells transfected
with the TOPFlash or FOPFlash reporter plasmids in presence or absence of
5-ASA treatment or KLF4 overexpression. The x-axis, combination of
transfected plasmids; y-axis, fold change of b-galactosidase normalized
luciferase values. Bars represent fold changes of luciferase activity  s.e.m.
of at least three independent experiments.
Figure 5.
A, Effects of 5-ASA treatment on miRNAs expression in the CaCo2 cell
line. Histograms indicate the expression of miRNAs-targeting KLF4,
predicted by Target Scan, analyzed by QRT-PCR. Results are
represented as mean  s.e.m. values of three independent experiments
and asterisks () indicate statistically significant results (P < 0.05). UT,
untreated cells; 5-ASA, cells treated with 5-ASA. B, Western blot analysis
of CaCo2 cells transfected with anti–miR-130a and anti–miR-135b
miRNA inhibitors. Cells were lysed 48 hours post-transfection. C, Cell
count performed on the same samples of B. Bars represent cell
numbers  s.e.m. of three independent experiments.
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conditions. Although not statistically significant, the
lower cell counts of samples transfected with miRNA
inhibitors, compared with controls, is in accord with an
increase of KLF4 expression.
Discussion
Previous work suggested that treatment with 5-ASA
might be chemopreventive for colorectal cancer
(6, 19). In particular, treatment with 5-ASA induced m-pro-
tocadherin expression, promoting the sequestration of
b-catenin to the plasmamembrane and, consequently, the
inactivation of Wnt/b-catenin signaling. In this study, we
provide further insight on the chemopreventive activity of
5-ASA, suggesting the existence of a dual mechanism of
b-catenin inactivation dependent on the transcription fac-
tor (TF) KLF4. This TF is not only known for its role in stem
cells but also because its expression is often deregulated in
cancer. For instance, its deletion in the intestinal epitheli-
um results in an increase in the number and migration of
epithelial cells and in the activation of genes of the Wnt
pathway (20). Moreover, its expression is lost in colorectal
cancer (21) and KLF4 is involved in methylation and "loss
of heterozygosity" disease-related events (22).
In this study, we provide evidence that 5-ASA, besides
inducing m-protocadherin, also activates KLF4 expression
and that the latter is directly responsible for 5-ASA–depen-
dent m-protocadherin expression. This conclusion is based
on the finding that KLF4 silencing suppresses 5-ASA–
mediated m-protocadherin expression and the results of
luciferase reporter assays demonstrating the presence of a
functional KLF4-binding site in the m-protocadherin pro-
moter. As previously reported (10), KLF4 is also capable of
directly binding and sequestering b-catenin in the nucleus.
Here we confirm by co-immunoprecipitation experiments
that, upon 5-ASA treatment, KLF4 interacts with b-catenin
preventing its binding to TCF4. On the basis of these
findings, we suggest that 5-ASA inhibits the Wnt/b-catenin
pathway by sequestering b-catenin to the plasma mem-
brane (m-protocadherin mediated) and by inhibiting its
transcriptional activity in the nucleus (KLF4 mediated).
KLF4 plays a pivotal role in both mechanisms because it
directly drives m-protocadherin expression.
To address potential mechanisms involved in
5-ASA regulation of KLF4 expression, we analyzed by
QRT-PCR the levels of several micro-RNAs in CaCo2 cells
treated with 5-ASA. We found that, among several others,
miR-130a andmiR-135b are strongly downregulated by 5-
ASA treatment. Bothmicro-RNAs are involved in cancer. In
particular, upregulation of miR-135b promotes chemo-
resistance (23) and cancer progression (24) in colorectal
cancer, whereas miR-130a is associated with drug resis-
tance and acts as an intermediate in the Wnt/b-catenin
pathway (25). More importantly, both microRNAs were
shown to downregulate KLF4 expression (26), supporting
the idea that their decreased expression plays an important
role in the 5-ASA–mediated increase in KLF4 expression.
Altogether, these data further strengthen the notion that 5-
ASA has a chemopreventive role in colorectal cancer pro-
viding a more complex picture of its mechanism of action,
as shown in Fig. 6.
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